Description

Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-Kinase/protease–C27H35N3O6S—-[1]Ruscoe JE, et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther. 2001 Jul;298(1):339-45.|[2]Galili N, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012 May 6;5:20–168682-53-9–529.65–99.19–O=C(OCC)[C@@H](C1=CC=CC=C1)NC([C@@H](NC(CC[C@H](N)C(OCC)=O)=O)CSCC2=CC=CC=C2)=O–Cancer–DMSO : 100 mg/mL (ultrasonic)|Ethanol : ≥ 100 mg/mL–Apoptosis;Glutathione S-transferase—-Apoptosis;Metabolic Enzyme/Protease–Peptides